ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Breast Cancer
Carcinoma

Lung Cancer trials near Salt Lake City, UT, USA:

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 210 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Salt Lake City, Utah, United States and 30 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Salt Lake City, Utah, United States and 256 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

as a single agent and in combination with pembrolizumab in subjects with locally advanced and unresectable or metastatic non-small cell lung ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Salt Lake City, Utah, United States and 26 other locations

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer...

Enrolling
Non-Small Cell Lung Cancer
Drug: Telisotuzumab Vedotin

Phase 2

AbbVie
AbbVie

Ogden, Utah, United States of America and 58 other locations

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Salt Lake City, Utah, United States and 117 other locations

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of ...

Enrolling
Large Cell Neuroendocrine Carcinoma of the Lung
Small-Cell Lung Cancer (SCLC)
Drug: 225Ac-ABD147

Phase 1

Abdera Therapeutics Inc.

Salt Lake City, Utah, United States and 4 other locations

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung...

Active, not recruiting
Relapsed Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

Pharma Mar

Salt Lake City, Utah, United States and 210 other locations

Study of Oral MRT-2359 in Selected Cancer Patients

This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small ce ...

Enrolling
L-MYC and N-MYC Amplified Solid Tumors
Prostate Cancer
Drug: Oral MRT-2359

Phase 1, Phase 2

Monte Rosa Therapeutics

West Valley City, Utah, United States and 21 other locations

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) ex...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: platinum-based chemotherapy
Drug: furmonertinib 240 mg oral, daily

Phase 3

ArriVent BioPharma
ArriVent BioPharma

Salt Lake City, Utah, United States and 207 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems